Intuniv XR: first alpha agonist approved for ADHD
Shire Canada is introducing Intuniv XR (guanfacine 1 mg, 2 mg, 3mg, and 4 mg extended-release tablets), the first selective alpha2A-adrenergic receptor agonist to be approved for the treatment of attention deficit hyperactivity disorder (ADHD) in Canada.